Heart Failure (HF) is a devastating disease affecting more than 300,000 Australians, and 11 million people in the US and Europe, with an incidence of 1.1 million new cases per year. Furthermore, current growth rates predict a 25% increase in the incidence of HF by 2030 .
The US National Institute of Health (NIH) estimated that 100,000 patients could immediately benefit from a VAD or TAH, and the European market is similarly sized. Patients with severe heart failure have a bleak outlook without intervention. In severe HF patients, drug therapy is a limited and less effective option, and whilst a heart transplant would meet their needs, only 4000 donor hearts are available globally each year.
 Miller, L. W. (2008), ‘Heart Failure: Who We Treat Versus Who We Study’, Cardiology Clinics, 26, 113-125.
 AIHW:. Field B 2003. Heart failure…what of the future? Bulletin no. 6. AIHW Cat. No. AUS 34. Canberra: AIHW.
 Heidenreich PA, et al.(2011), ‘Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association’, Circulation. 2011
 Thoratec Corporation (2007), Thoratec Corporation Annual Report 2007, (Online), Available from: http://media.corporate-ir.net/media_files/irol/95/95989/reports/AR2007.pdf [Accessed: 19th May 2010]
 DiGiorgi, P. L., et al. (2005), ‘Heart transplant and left ventricular assist device costs’, J Heart Lung Transplant, 24, 200-204.